Overview

A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants

Status:
Recruiting

Trial end date:
2025-06-16

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of samuraciclib in combination with fulvestrant versus fulvestrant alone in adult participants with metastatic or locally advanced Hormone Receptor (HR) positive and Human Epidermal Growth Factor Receptor (HER)2-negative breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Carrick Therapeutics Limited

Collaborator:

Pfizer

Treatments:

Fulvestrant